Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Insulin Resistance and Androgen Deprivation Therapy
NCT04995978 · St. Louis University · PHASE2 · withdrawn · last registry update 2023-06-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No participants were recruited and the study was deemed not feasible” | – | Registry record, St. Louis University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPARG within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-06-21Results posted on the registry: Shire, 25 mg Ontamalimab + 75 mg Ontamalimab (NCT03283085)
- 2024-06-11Results posted on the registry: Biogen, Bardoxolone methyl oral capsule + Placebo oral capsule (NCT03918447)
- 2024-06-05Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Bezafibrate 400 mg in addition to UDCA therapy + Bezafibrate 200 mg in addition to UDCA therapy (NCT06443606)
- 2024-05-23Phase 3 first posted: Zydus Therapeutics Inc., Saroglitazar Magnesium 1 mg (NCT06427395)
- 2024-05-08Also stopped (terminated): University Hospital Regensburg, low-dose Azacitidine + Pioglitazone (NCT02942758)
- 2024-03-19Results posted on the registry: Biogen, Bardoxolone methyl (NCT03749447)
- 2024-02-07Phase 3 first posted: The University of Texas Health Science Center at San Antonio, Tirzepatide + Pioglitazone (NCT06246799)
- 2023-12-19Phase 3 first posted: Faes Farma, S.A., Mesalazine (NCT06176560)
- 2023-10-30Phase 3 first posted: University of Basrah, Insulin Glargine 100 UNT/ML Pen Injector [Lantus] + Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg (NCT06107153)
- 2023-10-27Also stopped (terminated): Biogen, 20 mg bardoxolone methyl + Placebo (NCT01500798)
- 2023-10-12Results posted on the registry: Biogen, Bardoxolone methyl (NCT03068130)
- 2023-10-11Results posted on the registry: Biogen, Placebo Oral Capsule + Bardoxolone Methyl (NCT03019185)
- 2023-09-26Also stopped (terminated): Kyowa Kirin Co., Ltd., Bardoxolone methyl + Placebo (NCT03550443)
- 2023-08-15Also stopped (withdrawn): State University of New York at Buffalo, Pioglitazone 30 mg + Placebo (NCT05098327)
- 2023-08-14Phase 3 first posted: Mostafa Bahaa, Mesalamine + Nifuroxazide (NCT05988528)
- 2023-08-14Phase 3 first posted: Mostafa Bahaa, Mesalamine + Dapagliflozin 10mg Tab (NCT05986136)
- 2023-07-14Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Pioglitazone (ACTOS®) + Placebo of Pioglitazone (NCT05946564)
- 2023-05-19Results posted on the registry: Biogen, Placebo capsules + Bardoxolone methyl capsules (NCT02657356)
- 2023-05-15Also stopped (withdrawn): St. Louis University, Pioglitazone 30 Mg Oral Tablet + Pioglitazone placebo tablet (NCT04658849)
- 2023-04-19Phase 3 first posted: Minoryx Therapeutics, S.L., Leriglitazone + Placebo (NCT05819866)
- 2023-03-21Also stopped (terminated): University of Chicago, depot leuprolide plus estrogen/progestin replacement + pioglitazone (NCT00203996)
- 2023-03-08Results posted on the registry: National Cancer Institute (NCI), Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet (NCT02917629)
- 2023-03-08Also stopped (terminated): National Cancer Institute (NCI), Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet (NCT02917629)
- 2023-03-03Phase 3 first posted: Tanta University, Mesalamine + Fenofibrate 160mg (NCT05753267)
- 2023-02-24Results posted on the registry: University of Guadalajara, Berberine + Bezafibrate (NCT02548832)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision